Financial tombstone marking the initial public offering of stock by Cambridge, Massachusetts-based biotech firm Bluebird. The company focuses on gene therapies addressing both genetic and orphan diseases.
(3AHH048)Financial tombstone marking the initial public offering of stock by Cambridge, Massachusetts-based biotech firm Bluebird. The company focuses on gene therapies addressing both genetic and orphan diseases.
(3AHH048)